Adamas Pharmaceuticals (Adamas Pharmaceuticals) Additional Paid-In Capital : $528.05 Mil(As of Sep. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Adamas Pharmaceuticals Additional Paid-In Capital?

Adamas Pharmaceuticals's quarterly additional paid-in capital increased from Mar. 2021 ($523.75 Mil) to Jun. 2021 ($526.12 Mil) and increased from Jun. 2021 ($526.12 Mil) to Sep. 2021 ($528.05 Mil).

Adamas Pharmaceuticals's annual additional paid-in capital increased from Dec. 2018 ($432.82 Mil) to Dec. 2019 ($446.94 Mil) and increased from Dec. 2019 ($446.94 Mil) to Dec. 2020 ($455.28 Mil).

Adamas Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Adamas Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adamas Pharmaceuticals Additional Paid-In Capital Chart

Adamas Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Additional Paid-In Capital

Get a 7-Day Free Trial

254.56

277.96

432.82

446.94

455.28

Adamas Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Additional Paid-In Capital	Get a 7-Day Free Trial															452.33	455.28	523.75	526.12	528.05

Adamas Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Adamas Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adamas Pharmaceuticals Inc (NAS:ADMS) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Powell Street, Suite 1000, Emeryville, CA, USA, 94608

Website

http://www.adamaspharma.com

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

Executives

Vijay Shreedhar	officer: Chief Commercial Officer	C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608
Christopher B Prentiss	officer: Chief Financial Officer	1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608
Anna Richo	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David L Mahoney	director	SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Mardi Dier	director	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
William W. Ericson	director, 10 percent owner	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
John A Macphee	director	C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Ivan M Lieberburg	director	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Michael Bigham	director	890 WINTER STREET, WALTHAM MA 02451
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Neil F. Mcfarlane	officer: Chief Executive Officer	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Alfred G Merriweather	officer: Chief Financial Officer
Jennifer J Rhodes	officer: CBO, GC & Compliance Officer	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Gregory T Went	director, officer: Chief Executive Officer	C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608
Rajiv Patni	officer: Chief Medical Officer	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301